Although a formal economic analysis will be needed to justify offering AFP testing as a concrete complimentary option, we believe that developed societies could afford the cost of the false-positive AFP results added to the 90% true positives at least in cirrhotic patients in whom the sensitivity of US for early tumors is disappointing and the risk of HCC is highest,[36] if that improved survival, as in our findings. This evidence concerns the gene AFP and hepatocellular carcinoma.